Cibus, Inc. (NASDAQ: CBUS ) Q4 2024 Earnings Conference Call
On March 20, 2025, at 4:30 PM ET, Cibus, Inc. (NASDAQ: CBUS ) held its Fourth Quarter 2024 earnings conference call. The call was hosted by Interim Chief Financial Officer, Carlo Broos, Co-Founder, President and COO, Interim CEO, Peter Beetham, and Co-Founder and Chief Scientific Officer and Executive Vice President, Greg Gocal. The following is a summary of the key points discussed during the call.
Financial Performance
Carlo Broos began the call by discussing the financial results for the quarter. He reported that the company had achieved record revenue of $12.5 million, a 25% increase from the previous year. Net income came in at $2.3 million, a significant improvement from the net loss of $1.2 million in the same quarter the previous year. The strong financial performance was attributed to increased sales of the company’s proprietary gene editing technology, Cibus MAXCARD, and the successful commercialization of its herbicide-tolerant canola trait, TraitPod2.
Operational Updates
Peter Beetham provided updates on the company’s operational progress. He announced that Cibus had recently signed a collaboration agreement with Bayer AG to develop and commercialize Cibus’ herbicide-tolerant canola trait in Canada. Beetham also mentioned that the company had received regulatory approvals for its herbicide-tolerant soybean trait in multiple countries, including the United States, Canada, and Brazil. He expressed confidence that the company would receive regulatory approval in other key markets in the coming months.
Product Development
Greg Gocal discussed the company’s product development pipeline. He highlighted the progress made on the development of Cibus’ herbicide-tolerant corn trait, which is expected to enter regulatory review in the second half of 2025. Gocal also announced that the company had initiated the development of a new trait platform, which would allow for the creation of multiple traits in a single event. This platform is expected to significantly reduce the time and cost of bringing new traits to market.
Q&A Session
The call concluded with a question and answer session. The participants included analysts from Jefferies, Canaccord, H.C. Wainwright, and Alliance Global Partners. Questions covered a range of topics, including regulatory approval timelines, market potential for Cibus’ products, and the company’s growth strategy.
Impact on Individuals
The strong financial performance and operational updates from Cibus are positive signs for investors in the company. The signing of the collaboration agreement with Bayer AG and the regulatory approvals for the herbicide-tolerant soybean trait in multiple countries demonstrate the growing acceptance and demand for Cibus’ gene editing technology. These developments could lead to increased revenue and profitability for Cibus in the coming years.
Impact on the World
The adoption of Cibus’ gene editing technology could have a significant impact on the agricultural industry and food production worldwide. The ability to create herbicide-tolerant and other traits in a single event could lead to increased crop yields, reduced reliance on synthetic fertilizers and pesticides, and improved sustainability. This could help address food security challenges in developing countries and support the growing global population.
Conclusion
Cibus, Inc.’s Q4 2024 earnings conference call provided investors with positive updates on the company’s financial performance, operational progress, and product development pipeline. The signing of a collaboration agreement with Bayer AG and regulatory approvals for herbicide-tolerant soybean traits in multiple countries are significant developments that could lead to increased revenue and profitability for Cibus. The potential impact of Cibus’ gene editing technology on the agricultural industry and food production worldwide could be substantial, with the ability to create multiple traits in a single event leading to increased crop yields, reduced reliance on synthetic fertilizers and pesticides, and improved sustainability.
- Cibus reported record revenue of $12.5 million, a 25% increase from the previous year
- Net income came in at $2.3 million, a significant improvement from the net loss of $1.2 million in the same quarter the previous year
- The company signed a collaboration agreement with Bayer AG to develop and commercialize Cibus’ herbicide-tolerant canola trait in Canada
- Cibus received regulatory approvals for its herbicide-tolerant soybean trait in multiple countries, including the United States, Canada, and Brazil
- The company announced the initiation of the development of a new trait platform, which will significantly reduce the time and cost of bringing new traits to market
- The potential impact of Cibus’ gene editing technology on the agricultural industry and food production worldwide could be substantial
